Clinical Trial Detail

NCT ID NCT02862275
Title Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
Recruitment Recruiting
Gender both
Phase Phase 0
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Atezolizumab

Age Groups: senior adult

No variant requirements are available.